Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2007

bioMérieux to Design Companion Test for Ipsen Breast Cancer Compound

  • bioMérieux agreed to develop a companion test for Ipsen’s Phase I breast cancer drug candidate. The assay is intended for both the clinical development of the compound as well as a diagnostic test  potentially for future commercialization.

    BN 83495 is designed to block the steroid sulfatase enzyme (STS), which is found in hormone-dependent breast cancer in postmenopausal women. bioMérieux will devise a tool to determine the patients best suited to benefit from this STS inhibitor.

    The test will be developed on bioMérieux’ NucliSENS EasyQ® molecular diagnostics platform, using the NASBA® amplification technology. The company will will co-fund the project with Ipsen.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »